Shao Lili, Wang Xiaoli, Yu Qiongzhu, Gong Jun, Zhang Xiaodong, Zhou Yan
Department of Oncology, Tumor Hospital Affiliated to Nantong University & Nantong Tumor Hospital, Nantong, China.
Department of Pathology, The Affiliated Changshu Hospital of Xuzhou Medical University, Suzhou, China.
J Thorac Dis. 2022 Dec;14(12):4938-4950. doi: 10.21037/jtd-22-1696.
Extracellular nucleotidase on the cell surface CD39 plays a crucial role in the tumor microenvironment in the immunosuppressive adenosine pathway. However, the association between CD39 and lung adenocarcinoma has rarely been recorded. This study aimed to explore the involvement of CD39 in the biological processes of lung cancer.
First, a prediction model was established by analyzing the expression of CD39 in lung adenocarcinoma and its relationships with clinical evidence of lung adenocarcinoma using The Cancer Genome Atlas (TCGA) and Tumor IMmune Estimation Resource (TIMER) databases. In the TCGA and TIMER databases, the relationship between CD39 and immune cells and the relationship with immune-related expressed genes were studied. Subsequently, using gene set enrichment analysis (GSEA), the potential mechanism of action was investigated.
Lung adenocarcinoma patients with elevated CD39 expression had improved overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). CD39 expression was reduced in lung adenocarcinoma tumor tissue in the TCGA and TIMER databases. The nomogram's C-index was 0.688 (0.665-0.712), indicating some consistency in the prediction model. According to the TIMER and TCGA databases, CD39 expression was strongly connected with several immune cells invading and with immune checkpoint-related markers such as PDCD1, CD274, CTLA-4, and several functional T cells. GSEA revealed that CD39 influences the extracellular matrix, immunological microenvironment, programmed death 1 (PD-1) expression, glucose metabolism, PTEN stability, inflammatory response, and angiogenesis in lung cancer.
The current study's findings demonstrated that CD39 can be employed as a possible predictive biomarker for lung adenocarcinoma and may enhance the patients' poor prognosis by preventing the immunological escape of tumor cells from the lung adenocarcinoma tumor microenvironment.
细胞表面的胞外核苷酸酶CD39在免疫抑制腺苷途径的肿瘤微环境中起关键作用。然而,CD39与肺腺癌之间的关联鲜有报道。本研究旨在探讨CD39在肺癌生物学过程中的作用。
首先,通过使用癌症基因组图谱(TCGA)和肿瘤免疫评估资源(TIMER)数据库分析肺腺癌中CD39的表达及其与肺腺癌临床证据的关系,建立预测模型。在TCGA和TIMER数据库中,研究CD39与免疫细胞的关系以及与免疫相关表达基因的关系。随后,使用基因集富集分析(GSEA)研究潜在的作用机制。
CD39表达升高的肺腺癌患者总生存期(OS)、疾病特异性生存期(DSS)和无进展生存期(PFI)得到改善。在TCGA和TIMER数据库中,肺腺癌肿瘤组织中CD39表达降低。列线图的C指数为0.688(0.665 - 0.712),表明预测模型具有一定的一致性。根据TIMER和TCGA数据库,CD39表达与几种免疫细胞浸润以及免疫检查点相关标志物如PDCD1、CD274、CTLA - 4和几种功能性T细胞密切相关。GSEA显示,CD39影响肺癌中的细胞外基质、免疫微环境、程序性死亡1(PD - )表达、糖代谢、PTEN稳定性、炎症反应和血管生成。
本研究结果表明,CD39可作为肺腺癌可能的预测生物标志物,并可能通过防止肿瘤细胞从肺腺癌肿瘤微环境中免疫逃逸来改善患者的不良预后。